HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Indication and duration of the prednisolone therapy of chronic pulmonary sarcoidosis--a prognostic-therapeutic screening as a result of a controlled trial.

Abstract
Report on a controlled therapeutic trial with prednisolone of chronic pulmonary sarcoidosis. The patients comprised three groups differing from the dose of prednisolone and the duration of the treatment. 194 clinically and histologically proven cases were completely treated. Two years after ending the treatment the relapse rates were about 20 to 30% in each group. This corresponds well with the rate of spontaneous regression. These results are an indicator that in most cases the underlying pathogenic process of immune deficiency is calming down during treatment and this leads to a possible change in therapeutic indication:--treating all patients for only one year, --taking into account that a relapse will occur in about one third of all cases,--avoiding supertreatment of the other two thirds with a not harmless and costly drug.
AuthorsD Böttger
JournalZeitschrift fur Erkrankungen der Atmungsorgane (Z Erkr Atmungsorgane) Vol. 149 Issue 1 Pg. 148-52 (Jul 1977) ISSN: 0303-657X [Print] Germany
PMID607619 (Publication Type: Journal Article)
Chemical References
  • Prednisolone
Topics
  • Chronic Disease
  • Humans
  • Lung Diseases (drug therapy)
  • Prednisolone (administration & dosage, therapeutic use)
  • Prognosis
  • Sarcoidosis (drug therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: